原发性肝癌患者疼痛与血清HIF-1及VEGF水平的相关性分析

doi:10.3969/j.issn.1006-6233.2019.03.022

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1209 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the relationship between pain and serum levels of hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) in patients with primary liver cancer. Methods: From January 2016 to November 2017, 94 patients with hepatocellular carcinoma were divided into three groups according to visual analogue scale (VAS). Thirty patients were divided into pain-free group, 39 patients in general pain group and 25 patients in severe pain group. The expression level of HIF-1 and VEGF mRNA, serum levels of HIF-1 and VEGF were measured by ELISA. Results: There was a significant difference in VAS between the three groups (P<0.05). The relative expression of HIF-1 mRNA and VEGF mRNA, serum HIF-1 and VEGF levels in severe pain group were significantly higher than those in painless group and general pain group. The relative expression of HIF-1 mRNA and VEGF mRNA, serum HIF-1 and VEGF levels in general pain group were significantly higher than those in painless group (P<0.05). VAS score was positively correlated with HIF-1 and VEGF (r>0, P<0.05). Conclusion: The expression of HIF-1 and VEGF in patients with hepatocellular carcinoma has a certain correlation with the degree of pain, which provides a new idea for clinical relief of pain in patients with hepatocellular carcinoma and has important clinical value

Key words： Primary liver cancer Pain Hypoxia inducible factor -1 Vascular endothelial growth factor Correlation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2019.03.022 OR http://www.hbyxzzs.cn/EN/Y2019/V25/I3/615